MaxCyte, Inc. Notice of AGM and Change of Director (8000N)
October 01 2021 - 10:48AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 8000N
MaxCyte, Inc.
01 October 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Annual General Meeting
Change of Director
Gaithersburg, Maryland - 1 October 2021: MaxCyte, Inc ( NASDAQ:
MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization ,
announces that formal notice and resolutions of the Company's
Annual General Meeting (AGM), have been circulated to
Shareholders.
These documents are also available in electronic form on the
Company's website: www.maxcyte.com.
In addition, on September 30, 2021, Dr. J. Stark Thompson
notified the board of directors (the "Board") of the Company that
he will not stand for re-election at the Annual Meeting of
Stockholders to be held on October 29, 2021 (the "Annual Meeting").
Dr. Thompson will serve out his remaining term as a director and as
Chairman of the Board, which will expire upon the conclusion of the
Annual Meeting. Dr. Thompson's decision is not related to any
disagreement relating to the Company's operations, policies or
practices. He will continue to provide consulting services to the
Company as requested, during which time his outstanding stock
option awards will continue to vest in accordance with their terms
for so long as Dr. Thompson provides continuous service to the
Company. Following the Annual Meeting, the authorized size of the
Board will be eight members, and the Board will appoint a new
Chairman.
"On behalf of the Board and the entire MaxCyte team, we wish to
thank Dr. Thompson for his service and guidance on the Board over
the years," said Doug Doerfler, Chief Executive Officer.
For further information, please contact:
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: three instruments, the ATx(TM), STx(TM) and
GTx(TM); a portfolio of proprietary related processing assemblies
or disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAMBBITMTIMBIB
(END) Dow Jones Newswires
October 01, 2021 10:48 ET (14:48 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024